Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma

NCT00058422 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

65

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma

Interventions

BIOLOGICAL: darbepoetin alfa
BIOLOGICAL: filgrastim
BIOLOGICAL: rituximab
DRUG: cyclophosphamide
DRUG: doxorubicin hydrochloride
DRUG: prednisone
DRUG: vincristine sulfate
RADIATION: indium In 111 ibritumomab tiuxetan
RADIATION: yttrium Y 90 ibritumomab tiuxetan

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]